Richard Daniell, Executive VP, European Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), sold 280,744 shares at $15.73 ($4.4M) on 2025-03-04, disclosed to the SEC on 2025-03-06.
Scheduled sale ($4.4M) by Executive VP, European Commercial under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.73 | 13,353 | $210K | 4.7% |
| 2 | $15.73 | 13,353 | $210K | 4.7% |
| 3 | $15.73 | 21,870 | $344K | 7.8% |
| 4 | $15.73 | 21,870 | $344K | 7.8% |
| 5 | $15.73 | 56,385 | $887K | 20.0% |
| 6 | $15.73 | 56,385 |
| $887K |
| 20.0% |
| 7 | $15.91 | 7,108 | $113K | 2.6% |
| 8 | $15.91 | 7,108 | $113K | 2.6% |
| 9 | $15.91 | 11,641 | $185K | 4.2% |
| 10 | $15.91 | 11,641 | $185K | 4.2% |
| 11 | $15.91 | 30,015 | $478K | 10.8% |
| 12 | $15.91 | 30,015 | $478K | 10.8% |
| Total | $15.79 avg | 280,744 | $4.4M | 100% |
| Filing → |
| TEVA | SELL | 2026-03-06 | $6.0M | — | Filing → |
| TEVA | SELL | 2026-03-05 | $8.3M | — | Filing → |
| TEVA | SELL | 2025-12-11 | $6.6M | — | Filing → |